Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.60 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.58 |
| ▸ | TNF | P01375 | 4/20 | 0.58 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.58 |
| ▸ | IL1B | P01584 | 3/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | MAP1LC3B | Q9GZQ8 | 8/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18270887 | 1.00 | CRBN (0.60) | CRBNIKZF3DDB1TNFIKZF1 | |
| SCHEMBL28608567 | 0.94 | CRBN (0.64) | CRBNIKZF3DDB1TNFIKZF1 | |
| SCHEMBL29505690 | 0.93 | CRBN (0.69) | CRBNIKZF3DDB1TNFIKZF1 | |
| SCHEMBL1978451 | 0.93 | CRBN (0.69) | CRBNIKZF3DDB1TNFIKZF1 | |
| SCHEMBL1398964 | 0.93 | CRBN (0.69) | CRBNIKZF3DDB1TNFIKZF1 | |
| SCHEMBL10192708 | 0.93 | CRBN (0.69) | CRBNIKZF3DDB1TNFIKZF1 | |
| SCHEMBL33677 | 0.93 | CRBN (0.69) | CRBNIKZF3DDB1TNFIKZF1 | |
| Hydrochloric Acid SCHEMBL27957670 | 0.92 | CRBN (0.67) | CRBNIKZF3DDB1TNFIKZF1 | |
| SCHEMBL19359318 | 0.89 | CRBN (0.54) | CRBNIKZF3DDB1TNFIKZF1 | |
| SCHEMBL19359315 | 0.89 | CRBN (0.54) | CRBNIKZF3DDB1TNFIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333443-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2017-11-23 | — | — | US | disclosed |
| WO-2017201069-A1 | OXOINDOLINE DERIVATIVES AS PROTEIN FUNCTION MODULATORS | BIOTHERYX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333443-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, CKS1B | CRBN 176/4885IKZF3 1/4885DDB1 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.